The efficacy and safety of low-dose roxadustat in combination with recombinant human erythropoietin for treating hemodialysis patients with moderate anemia: A retrospective cohort study
Clinical Nephrology · 2025
DOI: 10.5414/cn111433 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Yanfei Huang und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Anemia, Renal Dialysis, Erythropoietin, Glycine. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Huang, Y., Jiang, X., Shu, G., Li, H., Lin, J., Duan, Q., Cao, X., Cheng, M., & Zheng, Z. (2025). The efficacy and safety of low-dose roxadustat in combination with recombinant human erythropoietin for treating hemodialysis patients with moderate anemia: A retrospective cohort study. Clinical Nephrology. https://doi.org/10.5414/cn111433
Vancouver
Huang Y, Jiang X, Shu G, Li H, Lin J, Duan Q, et al. The efficacy and safety of low-dose roxadustat in combination with recombinant human erythropoietin for treating hemodialysis patients with moderate anemia: A retrospective cohort study. Clinical Nephrology. 2025. doi:10.5414/cn111433
BibTeX
@article{Huang2025,
author = {Huang, Yanfei and Jiang, Xinxin and Shu, Guiqin and Li, Hui and Lin, Jingjing and Duan, Qingqing and Cao, Xue and Cheng, Min and Zheng, Zhigui},
title = {The efficacy and safety of low-dose roxadustat in combination with recombinant human erythropoietin for treating hemodialysis patients with moderate anemia: A retrospective cohort study},
journal = {Clinical Nephrology},
year = {2025},
doi = {10.5414/cn111433}
}
EUVIMED